NS Partners Ltd Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

NS Partners Ltd lessened its position in Johnson & Johnson (NYSE:JNJGet Rating) by 0.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 138,227 shares of the company’s stock after selling 954 shares during the quarter. Johnson & Johnson accounts for approximately 1.5% of NS Partners Ltd’s portfolio, making the stock its 21st biggest position. NS Partners Ltd’s holdings in Johnson & Johnson were worth $24,418,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the business. Glassy Mountain Advisors Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth about $35,000. Retirement Financial Solutions LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $40,000. TD Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at about $48,000. VitalStone Financial LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after buying an additional 159 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Down 1.4 %

Shares of Johnson & Johnson stock opened at $154.41 on Friday. The firm has a market cap of $401.27 billion, a P/E ratio of 32.30, a P/E/G ratio of 2.67 and a beta of 0.53. The business has a 50-day moving average price of $159.89 and a 200 day moving average price of $165.86. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.67 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 3.08%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 99.58%.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on JNJ shares. Atlantic Securities cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Raymond James lowered their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. UBS Group began coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price for the company. Credit Suisse Group lifted their price target on Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.